Differential expression of sputum and serum autoantibodies in patients with chronic obstructive pulmonary disease
- 1 June 2021
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 320 (6) , L1169-L1182
Abstract
Chronic obstructive pulmonary disease (COPD) is a complex and progressive respiratory disease. Autoimmune processes have been hypothesized to contribute to disease progression; however, the presence of autoantibodies in the serum has been variable. Given that COPD is a lung disease, we sought to investigate whether autoantibodies in sputum supernatant would better define pulmonary autoimmune processes. Matched sputum and serum samples were obtained from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study and at the Guangzhou Institute of Respiratory Health (GIRH). Samples were collected from patients with varying severity of COPD, asymptomatic smokers, and healthy control subjects. IgG and IgM autoantibodies were detected in sputum and serum of all subjects in both cohorts using a broad-spectrum autoantigen array. No differences were observed in sputum autoantibodies between COPD and asymptomatic smokers in either cohort. In contrast, 16% of detectable sputum IgG autoantibodies were decreased in subjects with COPD compared to healthy controls in the ADEPT cohort. Compared to asymptomatic smokers, approximately 13% of detectable serum IgG and 40% of detectable serum IgM autoantibodies were differentially expressed in GIRH COPD subjects. Of the differentially expressed specificities, anti-nuclear autoantibodies were predominately decreased. A weak correlation between increased serum IgM anti-tissue autoantibodies and a measure of airspace enlargement was observed. The differential expression of specificities varied between the cohorts. In closing, using a comprehensive autoantibody array, we demonstrate that autoantibodies are present in subjects with COPD, asymptomatic smokers, and healthy controls. Cohorts displayed high levels of heterogeneity, precluding the utilization of autoantibodies for diagnostic purposes.Keywords
Funding Information
- RespiVert Ltd, Part of Janssen Pharamaceuticals (2017YFC1310600)
- National Key R&D Program of China
- Guangzhou Healthcare Collaborative Innovation Major Project (201604020012)
- Medical Foundation of Guangdong Province (C2017050)
- Gouvernement du Canada | Canadian Institutes of Health Research (PJT-159792)
This publication has 39 references indexed in Scilit:
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2018
- Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in EmphysemaAmerican Journal of Respiratory and Critical Care Medicine, 2016
- B Cell–Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking historyThorax, 2010
- Autoantibodies in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Relation between duration of smoking cessation and bronchial inflammation in COPDThorax, 2006
- The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2004
- Hypothesis: Does COPD have an autoimmune component?Thorax, 2003
- Ongoing airway inflammation in patients with COPD who do not currently smokeThorax, 2000
- Effect of Smoking Cessation on Airway Inflammation in Chronic BronchitisAmerican Journal of Respiratory and Critical Care Medicine, 1995